Who owns Aura Biosciences, Inc. (AURA)? Elite investor 13F holders
3 tracked elite investors reported holding Aura Biosciences, Inc as of 2026-06-30, including Caligan Partners, Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | AURA BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 30517561.00 USD | 4298248.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | AURA BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1236820.00 USD | 174200.000000 | Shares | add | Original filing |
| D.E. Shaw | AURA BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 478576.00 USD | 67405.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.